Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Rtw Biotech (RTW) Share Price

Intraday
Historical

Price	$2.12 on 30-01-2026 at 09:56:58
Change	$0.00 0%
Buy	$2.15
Sell	$2.12

Last Trade:	Sell 4,687.00 at $2.1218
Day's Volume:	42,082
Last Close:	$2.12
Open:	$2.12
ISIN:	GG00BKTRRM22

Day's Range	$2.10 - $2.12
52wk Range:	$1.08 - $2.32
Market Capitalisation:	$691.91m
VWAP:	$2.115073
Shares in Issue:	326.37m

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Rtw Biotech (RTW) Latest Trades
Sell*	4,687	$2.1218	Ordinary	09:32:40 - 30-Jan-26
Unknown*	1,500	$2.120685	Ordinary Currency Conversion	09:21:39 - 30-Jan-26
Sell*	31	$2.11	Automatic Execution	08:16:33 - 30-Jan-26
Sell*	576	$2.11	Automatic Execution	08:06:30 - 30-Jan-26
Sell*	2,434	$2.11	Automatic Execution	08:05:51 - 30-Jan-26
Sell*	2,566	$2.11	Automatic Execution	08:05:51 - 30-Jan-26
Sell*	600	$2.11	Automatic Execution	08:05:51 - 30-Jan-26
Unknown*	0	$2.12	SI Trade	08:05:51 - 30-Jan-26
Sell*	2,250	$2.11	Automatic Execution	08:05:51 - 30-Jan-26
Sell*	56,835	$2.12	Uncrossing Trade	16:35:21 - 29-Jan-26

See more Rtw Biotech trades

Rtw Biotech (RTW) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
30th Jan 2026 (Fri)	2.12	2.12	2.10	2.12	42,082
29th Jan 2026 (Thu)	2.16	2.16	2.12	2.12	635,345
28th Jan 2026 (Wed)	2.21	2.21	2.15	2.15	233,005
27th Jan 2026 (Tue)	2.18	2.21	2.18	2.21	121,003
26th Jan 2026 (Mon)	2.18	2.21	2.18	2.18	462,074
23rd Jan 2026 (Fri)	2.21	2.22	2.20	2.20	116,288
22nd Jan 2026 (Thu)	2.22	2.22	2.19	2.21	361,329
21st Jan 2026 (Wed)	2.16	2.23	2.15	2.21	1,058,668
20th Jan 2026 (Tue)	2.13	2.18	2.07	2.16	472,396
19th Jan 2026 (Mon)	2.13	2.16	2.11	2.15	278,395
16th Jan 2026 (Fri)	2.22	2.25	2.13	2.15	697,366
15th Jan 2026 (Thu)	2.28	2.30	2.22	2.23	522,343
14th Jan 2026 (Wed)	2.23	2.32	2.23	2.32	1,433,826
13th Jan 2026 (Tue)	2.24	2.26	2.24	2.25	775,694
12th Jan 2026 (Mon)	2.23	2.26	2.23	2.26	1,065,222
9th Jan 2026 (Fri)	2.16	2.24	2.16	2.24	362,986
8th Jan 2026 (Thu)	2.16	2.21	2.16	2.20	202,728
7th Jan 2026 (Wed)	2.16	2.19	2.16	2.16	171,672
6th Jan 2026 (Tue)	2.16	2.20	2.16	2.20	274,097
5th Jan 2026 (Mon)	2.18	2.19	2.17	2.19	342,057
2nd Jan 2026 (Fri)	2.16	2.18	2.16	2.17	367,350
1st Jan 2026 (Thu)	2.16	2.16	2.16	2.16	0
31st Dec 2025 (Wed)	2.22	2.22	2.16	2.16	47,175
30th Dec 2025 (Tue)	2.18	2.19	2.16	2.19	48,888

See more Rtw Biotech price history

Date	Source	Headline
Rtw Biotech (RTW) Regulatory News
23rd Jan 2026 7:00 am	RNS	Corxel completes $287 million Series D-1 financing
22nd Jan 2026 10:00 am	RNS	Director/PDMR Shareholding
21st Jan 2026 7:00 am	RNS	GSK to acquire RAPT Therapeutics
16th Jan 2026 7:00 am	RNS	Boston Scientific to acquire Penumbra
15th Jan 2026 7:00 am	RNS	Monthly Valuation Update and Factsheet
12th Jan 2026 7:00 am	RNS	Aktis announces $318 million IPO
2nd Jan 2026 7:00 am	RNS	Total Voting Rights
2nd Jan 2026 7:00 am	RNS	Total Voting Rights
18th Dec 2025 7:00 am	RNS	New investment in Yarrow Bioscience
12th Dec 2025 7:00 am	RNS	Monthly Valuation Update and Factsheet

See more Rtw Biotech regulatory news

Rtw Biotech (RTW) Share News

IN BRIEF: RTW Biotech's largest private investment completes financing

23rd Jan 2026 11:23

RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Corxel Pharmaceuticals Ltd, RTW's largest private investment, has completed Series D-1 financing worth USD287 million. Says Corxel is a clinical-stage biopharmaceutical company developing therapies for cardiometabolic conditions, and its lead candidate, CX11, is an oral GLP-1 receptor agonist for obese and overweight patients currently in a phase 2 US trial. Expects the financing proceeds to support the advancement of this trial, as well as a planned global phase 2 trial in type 2 diabetes mellitus and initial preparations for phase 3 studies and other cardiometabolic programmes. Read More

IN BRIEF: RTW Biotech welcomes GSK deal to buy RAPT Therapeutics

21st Jan 2026 11:37

RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Notes GSK PLC's announcement on Tuesday that it has agreed to acquire RAPT Therapeutics Inc. Says RAPT, a Californian biopharmaceutical company developing therapies for inflammatory and immunologic diseases, represented 0.15% of its net asset value as of December 31. The all-cash transaction values RAPT at USD2.2 billion, with shareholders to receive USD58 per share. RTW says the price represents a 65% premium to RAPT's closing price on Monday. Read More

See more Rtw Biotech news

FTSE 100 Latest

Value10,183.62

Change11.86

Rtw Biotech (RTW) Share Price

Login to your account